Effects of psychostimulants and antipsychotics on serum lipids in an animal model for schizophrenia

dc.citation.issue3
dc.citation.volume9
dc.contributor.authorCorreia, Banny Silva Barbosa
dc.contributor.authorNani, João Victor [UNIFESP]
dc.contributor.authorRicardo, Raniery Waladares
dc.contributor.authorStanisic, Danijela
dc.contributor.authorCosta, Tássia Brena Barroso Carneiro
dc.contributor.authorHayashi, Mirian Akemi Furuie [UNIFESP]
dc.contributor.authorTasic, Ljubica
dc.contributor.authorLatteshttp://lattes.cnpq.br/5559309395232147pt_BR
dc.coverageBasel
dc.date.accessioned2021-10-27T20:29:49Z
dc.date.available2021-10-27T20:29:49Z
dc.date.issued2021-02-26
dc.description.abstractSchizophrenia (SCZ) treatment is essentially limited to the use of typical or atypical antipsychotic drugs, which suppress the main symptoms of this mental disorder. Metabolic syndrome is often reported in patients with SCZ under long-term drug treatment, but little is known about the alteration of lipid metabolism induced by antipsychotic use. In this study, we evaluated the blood serum lipids of a validated animal model for SCZ (Spontaneously Hypertensive Rat, SHR), and a normal control rat strain (Normotensive Wistar Rat, NWR), after long-term treatment (30 days) with typical haloperidol (HAL) or atypical clozapine (CLZ) antipsychotics. Moreover, psychostimulants, amphetamine (AMPH) or lisdexamfetamine (LSDX), were administered to NWR animals aiming to mimic the human first episode of psychosis, and the effects on serum lipids were also evaluated. Discrepancies in lipids between SHR and NWR animals, which included increased total lipids and decreased phospholipids in SHR compared with NWR, were similar to the differences previously reported for SCZ patients relative to healthy controls. Administration of psychostimulants in NWR decreased omega-3, which was also decreased in the first episode of psychosis of SCZ. Moreover, choline glycerophospholipids allowed us to distinguish the effects of CLZ in SHR. Thus, changes in the lipid metabolism in SHR seem to be reversed by the long-term treatment with the atypical antipsychotic CLZ, which was under the same condition described to reverse the SCZ-like endophenotypes of this validated animal model for SCZ. These data open new insights for understanding the potential influence of the treatment with typical or atypical antipsychotics on circulating lipids. This may represent an outcome effect from metabolic pathways that regulate lipids synthesis and breakdown, which may be reflecting a cell lipids dysfunction in SCZ.pt_BR
dc.description.affiliationInstituto de Química, Universidade Estadual de Campinas (UNICAMP), Campinas 13083-970, Brazil
dc.description.affiliationNational Institute for Translational Medicine (INCT-TM, CNPq), Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), São Paulo 14049-900, Brazil
dc.description.affiliationDepartamento de Farmacologia, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04044-020, Brazil.
dc.description.affiliationUnifespDepartamento de Farmacologia, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo 04044-020, Brazil.
dc.format.extent15 p.
dc.identifierhttps://doi.org/10.3390/biomedicines9030235
dc.identifier.citationBiomedicines, Basel. v. 9, n. 3, p. 1-15, 26 Feb. 2021.pt_BR
dc.identifier.doi10.3390/biomedicines9030235
dc.identifier.issn2227-9059
dc.identifier.urihttps://hdl.handle.net/11600/62124
dc.languageengpt_BR
dc.publisherMDPI AGpt_BR
dc.relation.ispartofBiomedicinespt_BR
dc.rightsAcesso abertopt_BR
dc.subjectLipidomicspt_BR
dc.subjectSchizophreniapt_BR
dc.subjectAntipsychoticpt_BR
dc.subjectAnimal modelspt_BR
dc.titleEffects of psychostimulants and antipsychotics on serum lipids in an animal model for schizophreniapt_BR
dc.typeArtigopt_BR
unifesp.campusEscola Paulista de Medicina (EPM)pt_BR
unifesp.departamentoFarmacologiapt_BR
unifesp.graduateProgramFarmacologiapt_BR
unifesp.knowledgeAreaOutrapt_BR
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
biomedicines-09-00235-v4.pdf
Tamanho:
758.73 KB
Formato:
Adobe Portable Document Format
Descrição:
Licença do Pacote
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
5.7 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Coleções